HER2低表达乳腺癌的靶向治疗研究进展

Research progress on targeted therapy of breast cancer with low expression of HER2

乳腺癌目前已成为女性发病率最高的恶性肿瘤,其中人表皮生长因子受体2(HER2)阳性乳腺癌占比15%~20%。随着抗HER2靶向药物的不断发展,HER2阳性乳腺癌的生存及预后显著获益。乳腺癌中45%~55%的患者为HER2低表达,该类患者通常不再接受抗HER2治疗。但HER2低表达乳腺癌的生物学行为和预后与HER2零表达乳腺癌之间存在显著差异,对此进行区分并采取相应治疗策略有助于改善患者预后。目前关于HER2低表达乳腺癌的靶向治疗已有诸多研究进展,为HER2低表达乳腺癌的精准化治疗提供了有益参考。

Breast cancer has become the malignant tumor with the highest incidence rate among women,of which human epidermal growth factor receptor 2(HER2)positive breast cancer accounts for about 15%-20%.With the development of anti HER2 targeted drugs,the survival and prognosis of HER2 positive breast cancer has significantly benefited.About 45%-55%of breast cancer patients have low HER2 expression,and these patients usually do not receive anti HER2 treatment.However,there is a significant difference between the biological behavior and prognosis of breast cancer with low HER2 expression and breast cancer with zero HER2 expression.It is helpful to differentiate and adopt corresponding treatment strategies to improve the prognosis of patients.At present,there have been many advances in targeted therapy of breast cancer with low HER2 expression,which provides a useful reference for precision treatment of breast cancer with low HER2 expression.